Search This Blog

Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts

Tuesday, March 27, 2012

GE & Partners Announce Winners of the First Stage of $100 M "healthymagination Cancer Challenge"

Press release:

27 March 2012
GE & Partners Announce Winners of the First Stage of $100 Million “healthymagination Cancer Challenge”

· Challenge focused on early-stage breast cancer breakthroughs that warrant discovery, incubation and acceleration through seed funding
· Winning innovations could expedite breast cancer detection, diagnosis and improve the identification of effective therapies, allowing more patients to survive

SAN FRANCISCO--27 March 2012-- GE (NYSE: GE) announced today five innovation award winners as part of the first stage of its $100 million “GE healthymagination Cancer Challenge.” More than 500 ideas from 40 countries were submitted, sparking robust conversations among more than 200 academic institutions and researchers on the Challenge’s open innovation platform.
The five innovation award winners have the potential to help doctors find cancer earlier, make more accurate diagnoses and choose the best possible treatment based on each patient’s unique cancer. The submitted ideas include ones that could help doctors better understand the molecular similarities between breast cancer and other solid tumors with a particular focus on tumors associated with triple negative cancer, a type of cancer that is less responsive to standard treatments and is typically more aggressive. GE is committed to a new approach at healthymagination that shines a spotlight on early-stage ideas to accelerate the researchers’ work and ultimately help patients sooner.
Beth Comstock, senior vice president and chief marketing officer, GE said, “We launched the Challenge as a call to action for oncology researchers, businesses, and other innovators around the world to accelerate innovation and help stop this deadly disease. It is often challenging for early stage research to grab the attention of seed investors. The Challenge has shown us that there are a remarkable number of breakthrough ideas out there that deserve promotion, investment and incubation.”
In addition to the $100,000 seed award, GE will provide support for each winner through mentorship and access to GE researchers and industry thought leaders with opportunity for expanded partnerships in the future.
“GE and Clarient focus on helping health providers understand and define the drivers of a patient’s particular cancer. The Challenge winners' work will change the future of fighting cancer,” said Carrie Eglinton-Manner, general manager of Clarient, the cancer diagnostics company acquired by GE in 2010. “In addition to the grant money, we will help mentor, develop and accelerate the growth of these winning ideas.”
The winners were selected by a panel of judges that included venture capital partners, GE executives, and several leading healthcare luminaries including former U.S. FDA Commissioner and National Cancer Institute Director, Dr. Andrew Von Eschenbach; Professor of Surgery and Director of the University of Michigan Breast Care Center, Dr. Lisa Newman; and cancer medicine specialist and Imperial College’s professor of cancer medicine, Dr. Justin Stebbing.
The five innovation Challenge award winners are:
  • MyCancerGenome- Personalized Approach to Triple Negative Breast Cancer: Vanderbilt University in Nashville, Tennessee is developing MyCancerGenome, a free online cancer medicine resource and decision-making tool for physicians, patients, caregivers and researchers. It provides up-to-date information on what mutations make breast cancer grow and related treatment implications, including available genome-directed clinical trials for triple negative breast cancer.
  • Creating Safer & Stronger Breast Implants with Cancer-fighting and Healing Properties: The University of Akron in Akron, Ohio is developing new materials for breast reconstruction to transform tissue expanders and implants into cancer-fighting and healing devices. Using coatings embedded with pharmaceutical agents the new device is expected to help fight infection, reduce inflammation, and possibly even target and destroy stray cancer cells.
  • Identifying a Predisposition to Cancer Spread: Moffitt Cancer Center in Tampa, Florida is working to understand the genetic "modifier" genes and their role in predisposition to the spread of cancer to other parts of the body following cancer onset. This research could form the basis of diagnostic testing for genes that place a patient at disproportionate risk for cancer spread and guide aggressiveness of treatment.
  • Saving Lives in Developing Countries: For developing countries such as Uganda, breast ultrasound holds promise in identifying cancers in young women with palpable lumps. Fred Hutchinson Cancer Research Center in Seattle, Washington and Uganda Cancer Institute (UCI) in Kampala are establishing a breast cancer screening program where women will receive education about breast cancer and those with symptoms will be offered clinical breast exam and breast ultrasound. Women with suspicious lumps will be referred to the UCI for tissue sampling and, if malignancy is diagnosed, treatment.
  • Moving to Personalized Therapy for Triple Negative Breast Cancer: Researchers at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee have demonstrated that gene expression analysis reveals at least six distinct disease subtypes for triple negative breast cancer that likely respond differently to chemotherapy. Using this discovery, the Center is designing clinical trials with targeted therapy for select subtypes which will soon be offered to patients.
Information on the winners is available at www.healthymagination.com.
Launched in September, the Challenge is part of GE’s healthymagination commitment to accelerate cancer innovation by investing $1 billion in cancer technology research and development as well as improve care for 10 million cancer patients around the world by 2020. Additional strategic commercial partnership announcements from the Challenge will be made later in 2012. For additional details on the challenge, and to view the full terms and conditions visit healthymagination.com/challenge.
About GE
GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works. For more information, visit the company's website at www.ge.com.
About GE’s healthymagination Initiative
Launched in May 2009, GE’s healthymagination initiative is focused on four critical needs: low-cost technology; healthcare IT; innovation accessible to all; and consumer-driven healthcare. GE has committed that by 2015 it will:
  • Invest $3 billion in research and development to launch at least 100 innovations that will help deliver better care to more people at lower cost.
  • Provide $2 billion in financing and $1 billion in technology to bring healthcare information technology to rural and underserved areas.
  • Reduce the cost of procedures that use GE technologies and services by 15 percent and develop products tailored to underserved regions of the world.
  • Reach 100 million more people every year with services and technologies essential for health.
More information at www.healthymagination.com.

Wednesday, March 14, 2012

Teenager Unlocks Potential Pathways for Breast Cancer Treatments, Wins Intel Science Talent Search

Teenager Unlocks Potential Pathways for Breast Cancer Treatments, Wins Intel Science Talent Search

News Release from IBM - Biomedical Analytics

IBM's Biomedical Analytics Platform Helps Doctors Personalize Treatment

Italy's Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments
HAIFA, Israel & MILAN - 14 Mar 2012: IBM (NYSE: IBM) today announced it has developed a unique biomedical analytics platform for personalized medicine that could enable doctors to better advise on the best course of medical treatment. This could lead to smarter and more personalized healthcare in a wide-range of areas, including cancer management, hypertension, and AIDS care.
Scientists from IBM Research are collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori, a major research and treatment cancer center in Italy, on the new decision support solution. This new analytics platform is being tested by the Institute's physicians to personalize treatment based on automated interpretation of pathology guidelines and intelligence from a number of past clinical cases, documented in the hospital information system.
IBM’s Clinical Genomics
IBM’s Clinical Genomics biomedical analytics platform for personalized medicine.
Selecting the most effective treatment can depend on a number of characteristics including  age, weight, family history, current state of the disease and general health.  As a result, more informed and personalized decisions are needed to provide accurate and safe care.
IBM's latest healthcare analytics solution, Clinical Genomics (Cli-G), can integrate and analyze all available clinical knowledge and guidelines, and correlate it with available patient data to create evidence that supports a specific course of treatment for each patient. Developed at IBM Research - Haifa, the new prototype works by investigating the patient's personal makeup and disease profile, and combines this with insight from the analysis of past cases and clinical guidelines. The solution may provide physicians and administrators with a better picture of the patient-care process and reduce costs by helping clinicians choose more effective treatment options.
"Making decisions in today's complex environment requires computerized methods that can analyze the vast amounts of patient information available to ease clinical decision-making," notes Dr. Marco A. Pierotti, Scientific Director at the Istituto Nazionale dei Tumori. "By providing our physicians with vital input on what worked best for patients with similar clinical characteristics, we can help improve treatment effectiveness and the final patient outcome."
Founded in 1925, the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is recognized as a scientific research and treatment institution in the field of pre-clinical and clinical oncology. The Institute's special status as a research center enables it to transfer research results directly to clinical care. The Institute initiated this collaboration with IBM to enhance patient care through better use of innovative IT solutions. Once physicians make a diagnosis, they will receive personalized insights for their patients, based on medical information, automated interpretation of pathology clinical guidelines, and intelligence from a number of past clinical cases, documented in the hospital information system.
In addition to supporting decision-making about treatment, it can provide administrators at Fondazione IRCCS Istituto Nazionale dei Tumori with an aggregated view of patient care, enabling them to evaluate performances and using this knowledge to streamline processes for maximum safety. For example, hospital administrators can drill down into the data to better understand what the guidelines were for insights, what succeeded, and whether treatment quality has improved.
"Our clinical genomics solution may enable care-givers to personalize treatment and increase its chances of success," explains Haim Nelken, senior manager of integration technologies at IBM Research - Haifa. "The solution is designed to provide physicians with recommendations that go beyond the results of clinical trials. It may allow them to go deeper into the data and more accurately follow the reasoning that led to choices previously made on the basis of subjective memory, intuition, or clinical trial results."
Any patient data securely collected from hospitals and health organizations is 'de-identified' or made anonymous through the removal of personal identifying details. The IBM system does not need to know which individuals the information came from in order to draw conclusions. It works by identifying similar cases based on age, sex, symptoms, diagnosis, or other related factors.